A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)

This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.

Start Date15 Apr 2025

Sponsor / Collaborator

Resverlogix Corp.

NCT03160430

/ Not yet recruitingPhase 1/2

A Two-Part Phase 2a Study in Patients With End-Stage Renal Disease Treated With Hemodialysis; Part A is an Open-Label Study Arm to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of 100 mg RVX000222; and Part B is a Double-Blind, Randomized, Placebo-Controlled, Sequential Cross-Over Study Arm to Evaluate the Efficacy, Safety, and Pharmacokinetics of RVX000222

This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal Disease (ESRD) patients who receive hemodialysis as standard of care.
Part B of the study is a double-blind, placebo-controlled study in up to thirty six (36) ESRD patients receiving hemodialysis using a sequential cross-over design with RVX000222 at a daily oral dose of 100 mg b.i.d. (200 mg per day) or matching placebo in combination with SoC.
The primary objective of the study is to evaluate if treatment with RVX000222 in combination with standard of care (SoC) decreases plasma alkaline phosphatase in comparison to placebo and SoC.

Start Date22 Nov 2024

Sponsor / Collaborator

Resverlogix Corp.

NCT04915300

/ Unknown statusPhase 2IIT

Apabetalone for Pulmonary Arterial Hypertension: a Phase 2 Clinical Study

Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged. Short term placebo-controlled randomized trials assessing PAH-specific monotherapy with these molecules have reported improvements in pulmonary hemodynamics and exercise capacity. A recent meta-analysis also documented a reduction in short-term mortality of about ≈40% with such therapies. Several randomized clinical trials evaluating PAH-specific combination therapy have been conducted. Our recent meta-analysis showed that combination therapy was associated with a 35% risk reduction for the occurrence of clinical worsening compared to monotherapy. Nonetheless, the investigators also showed 17% of PAH patients receiving combination therapy still experienced clinical worsening over a median exposure of 16 weeks. Moreover, long-term survival on PAH-specific also therapy remains poor in the modern era, with a yearly mortality rate of 15 % in incident idiopathic PAH. The identification of innovative therapeutic targets and validation of these complementary therapeutic interventions are thus urgently needed in PAH.
The investigators and others (K. Stenmark, University of Colorado and H. Bogaard, VU University Medical Center, Amsterdam, personal communications), have published strong evidence that BRD4 plays a key role in the pathological phenotype in PAH accounting for disease progression and showed that BRD4 inhibition can reverse PAH in several animal models. Intriguingly, coronary artery disease (CAD) and metabolic syndrome are more prevalent in PAH compared with the global population, suggesting a link between these diseases. Interestingly, BRD4 is also a trigger for calcification and remodeling processes and regulates transcription of lipoprotein and inflammatory factors, all of which are important in PAH and CAD. Apabetalone, an orally available BRD4 inhibitor, is now in a clinical development stage with a good safety profile.
The overall objective of the study is to explore the efficacy and safety of apabetalone as an add-on therapy for adult PAH patients and to inform the conduct and the design of a Phase 3 trial.
The primary objective of the study is to assess the efficacy of apabetalone as evaluated by the change in PVR over a period of 24 weeks compared to placebo in adult subjects with PAH on stable background therapy.
Secondary objectives include changes at week 24 in 6MWD, plasma NT-proBNP concentration, WHO functional class, ESC/ERS risk stratification score, health-related quality of life and additional hemodynamic data from right heart.
Exploratory objectives are to evaluate the effects of apabetalone compared to placebo in adult subjects with PAH on mortality and clinically relevant morbidity events, and on circulating levels and transcription changes in whole blood markers of metabolism, vascular calcification, inflammation, DNA damage and leucocyte expression of BMPR2.

Start Date01 Oct 2023

Sponsor / Collaborator

Université Laval

[+2]

100 Clinical Results associated with Apabetalone

100 Translational Medicine associated with Apabetalone

100 Patents (Medical) associated with Apabetalone

136

Literatures (Medical) associated with Apabetalone

01 Jul 2026·BIOCHEMICAL PHARMACOLOGY

A resveratrol derivative RVX-208 inhibits PD-1/PD-L1 to restrain non-small cell lung cancer as an immunotherapy

Article

Author: Chen, Ziye ; Chen, Lishan ; Huang, Chongjun ; Liu, Shuwen ; Dai, Wenqi ; Liang, Qinghe ; Li, Ruopeng ; Li, Xiaojuan ; Chen, Fengsheng ; Chen, Yan

Immunotherapies, particularly anti-PD-1 antibodies, have emerged as standard first-line treatments for non-small cell lung cancer (NSCLC). RVX-208, derived from resveratrol, has recently completed Phase III clinical trials for atherosclerosis in the United States. In this study, we demonstrate for the first time that RVX-208 suppresses lung cancer growth in vivo by enhancing T cell-mediated immunity notably rather than directly suppressing lung cancer cell proliferation. Mechanically, RVX-208 interfered with janus kinase 2 (JAK2) to reduce its phosphorylation, reduced both the programmed death-1 (PD-1) expression in T lymphocytes and programmed death-ligand 1 (PD-L1) expression in lung cancer cells, thereby inhibiting the growth of lung cancer cells co-cultured with T lymphocytes in vitro. Furthermore, RVX-208 enhanced the anti-tumor activity of anti-PD-1 antibody in lung cancer cells that were co-cultured with lymphocytes in vitro. Consistent with these findings, RVX-208 treatment also reduced PD-1 levels in T cells from tumor bearing mice in vivo. Collectively, these results identify RVX-208 as a promising small-molecule immunotherapeutic agent for the treatment of lung cancer.

01 Feb 2026·Advanced Science

Brd4 BD1 Domain Antagonism of MS436 Preserves Blood‐Brain Barrier Integrity via Rnf43/β‐Catenin Signaling Pathway

Article

Author: Yong Zhang ; Yushan Du ; Xiaochen Zhang ; Fen Ji ; Jingjing Zhang ; Chenxiao Li ; Jiangwei Xia ; Jianwei Jiao ; Shuang Liu ; Shukui Zhang ; Sihan Li

Abstract:

Blood‐brain barrier (BBB) disruption is central to neurodegenerative and cerebrovascular diseases, but its causal role and therapeutic targeting remain challenging. Bromodomain and extraterminal domain (BET) proteins, particularly Brd4, regulate transcription via dual bromodomains (BD1, BD2). While BD1 antagonists are explored for tumors and BD2 antagonists for inflammation, their impact on cerebrovascular integrity is unclear. Crucially, opposing BBB effects of domain‐specific BET antagonism: the BD2 antagonist RVX208 disrupt the BBB, whereas the BD1 antagonist MS436 significantly reduces leakage and improves neurological outcomes, revealing therapeutic potential is demonstrated. Mechanistically, endothelial Brd4 critically suppresses BBB stability. Its ablation upregulates tight junction (TJ) proteins. Brd4, acting exclusively through its BD1 domain, destabilizes TJs via Rnf43 is identified, which promotes β‐catenin and TJ protein degradation. This defines a novel Brd4 BD1/Rnf43/β‐catenin axis essential for BBB integrity. The findings establish Brd4 BD1 inhibition as a novel BBB‐protective strategy and position MS436 for repurposing in cerebrovascular diseases, necessitating reevaluation of domain‐specific BET targeting for neurovascular pathologies.

01 Dec 2025·DRUG DISCOVERY TODAY

Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies

Review

Author: Lambona, Chiara ; Rota, Rossella ; Locatelli, Franco ; Zwergel, Clemens ; Marchese, Cinzia ; Cassandri, Matteo ; Macrì, Elisa ; Pomella, Silvia ; Barillari, Giovanni ; Ferraro, Erika

BET inhibitors (BETi), especially those targeting BRD4, show promising preclinical activity against pediatric sarcomas by disrupting oncogenic transcription. This systematic review of 26 studies highlights the anti-proliferative and pro-apoptotic effects of BETi across five pediatric sarcoma types. In vivo data show a decrease in tumor growth, with better results when combined with other therapies. This systematic review revealed that, whereas early investigations mostly rely on pan-BETi, recent studies focus on newer and more specific agents. Accordingly, we reported that ABBV-744 and RVX-208, which selectively target the BD2 domain, and GNE-987, a specific BRD4 degrader, are the most promising inhibitors. However, ABBV-075, a pan-BETi, also exhibits high efficacy, being effective at low doses. Nevertheless, translating these experimental findings into clinical practice remains difficult because of resistance, toxicity, and inconsistent responses. Future approaches include using biomarkers for patient selection, developing isoform-specific BETi, and designing rational combination therapies to enhance treatment for these aggressive pediatric cancers.

News (Medical) associated with Apabetalone

31 Mar 2026

·www.resverlogix.com

Resverlogix Corp. Provides Bi-Weekly MCTO Status Update

CALGARY, Alberta, March 31, 2026, Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is providing an update on the management cease trade order (“MCTO”) application it made to the Alberta Securities Commission (the “ASC”) under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"). The application remains under review, and no decision has yet been made by the ASC. The Company announced on March 17, 2026 (the “Original Announcement”) that it had been advised by its external auditor (the "Auditor") that the Auditor anticipated being unable to complete its audit of the ‎annual financial statements by March 31, 2026. Consequently, Resverlogix will default on the prescribed deadline of March 31, 2026 (the “Default”) for filing its annual audited financial statements, annual information form, and management discussion & analysis for the year ended December 31, 2025, ‎as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure ‎‎Obligations ("NI 51-102") and certification of the annual filings (collectively, the "Annual Filings"). The Default resulted from unavoidable delays on the part of the Company in beginning the audit process. The Company worked with the Auditor to overcome these initial delays and assign additional resources to the audit. The Company and the Auditor continue to work diligently to complete the Annual Filings as soon as possible. The Company expects, but cannot assure, that the audit and the Annual Filings will be completed by April 10, 2026, and will issue a news release once the Annual Filings have been filed.‎ The ASC may grant the application and issue the MCTO or it may impose an issuer cease trade order. Should the MCTO be granted, the Company’s Chief Executive Officer and Chief Financial Officer will be prohibited from all trading in the securities of the Company until such time as the Annual Filings are filed and the general investing public will continue to be able to trade freely in the Company's listed common shares during the term the MCTO is in effect. The Company confirms that since the date of the Original Announcement other than as described above, there has been no material change to the information set out in the Original Announcement that has not been generally disclosed. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 including the issuance of bi-weekly default status reports, in the form of news releases, for so long as the Company remains in default with the Annual Filings; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Annual Filings; (iii) the Company confirms that, as of the date of this news release, that the Company is not subject to any insolvency proceedings; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed. Until the ‎Company has filed the Annual Filings, members of the Company's management and other insiders are subject to an insider trading black-out. Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: www.linkedin.com/company/resverlogix-corp-/ This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts”, and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 www.resverlogix.com

18 Mar 2026

·www.biospace.com

Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A

Calgary, Alberta--(News - March 17, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces that because of delays in the completion of its year-end audit, the Company anticipates it will be unable to meet the prescribed deadline of March 31, 2026 for filing of the following continuous disclosure documents (collectively, the "Annual Filings"): Annual Audited Financial Statements, Annual Information Form, and Management Discussion & Analysis for the year ended December 31, 2025, ‎as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure ‎‎Obligations ("NI 51-102") and Certification of the Annual Filings;‎ The Company's auditor has advised the Company that it anticipates being unable to complete its audit of the ‎annual financial statements by March 31, 2026.‎ The Company expects, but cannot assure, that the audit and the Annual Filings will be completed by April 10, 2026.‎ Consequently, the Company has applied to the Alberta Securities Commission (the "ASC") for a management cease trade order (the "MCTO") under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") that, if granted, will prohibit the Company's Chief Executive Officer and Chief Financial Officer from all trading in the securities of the Company until such time as the Annual Filings are No decision has yet been made by the ASC on this application. The ASC may grant the application and issue the MCTO or it may impose an issuer cease trade order in the event that the Annual Filings are delayed. Should the MCTO be granted, the general investing public will continue to be able to trade freely in the Company's listed common shares during the term the MCTO is in effect. The Company and its auditor continue to work diligently to complete the Annual Filings as soon as possible and will issue a news release once the Annual Filings have been Until the Company files the Annual Filings, it will comply with the guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports, in the form of news releases. Until the ‎Company has filed the Annual Filings, members of the Company's management and other insiders are subject to an insider trading black-out. The Company confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments since the November 13, 2025 filing of the Company's ‎interim financial reports for the period ended September 30, 2025. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 To view the source version of this press release, please visit

18 Feb 2026

·www.resverlogix.com

Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement

CALGARY, Alberta, February 18, 2026, Resverlogix Corp. (“Resverlogix”) (TSX:RVX) announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the “Subscriber”) of Resverlogix’s Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the transaction, the Subscriber holds approximately 9.7% of Resverlogix's common shares. The common shares are subject to a four-month hold period. The shares-for-interest transaction followed the settlement of CAD$2.8 million of accrued interest on indebtedness owing to the Subscriber by Zenith Capital Corp. (“Zenith”) by way of the assignment to the Subscriber of an equal amount of accrued interest on indebtedness owing by Resverlogix to Zenith Capital Corp. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix's securities to, or for the account or benefit of, persons in the United States or U.S. Persons. Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: https://www-linkedin-com.sutd.idm.oclc.org/company/resverlogix-corp-/ This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts”, and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 www.resverlogix.com

100 Deals associated with Apabetalone

External Link

KEGG	Wiki	ATC	Drug Bank
D11131	Apabetalone	-	DB12000

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 3	Jordan	Resverlogix Corp.	15 Apr 2025
Post Acute COVID 19 Syndrome	Phase 3	Saudi Arabia	Resverlogix Corp.	15 Apr 2025
Post Acute COVID 19 Syndrome	Phase 3	United Arab Emirates	Resverlogix Corp.	15 Apr 2025
COVID-19	Phase 3	Canada	Resverlogix Corp.	14 Jan 2022
Angina, Unstable	Phase 3	Argentina	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Australia	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Belgium	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Bulgaria	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Croatia	Resverlogix Corp.	01 Nov 2015
Angina, Unstable	Phase 3	Germany	Resverlogix Corp.	01 Nov 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02586155 (BETonMACE, ERA2023)	Phase 3	Chronic Kidney Diseases	-	Apabetalone 100 mg	xtrsxtbnhf(njhwwuyfzj): HR = 0.5 (95% CI, 0.26 - 0.96), P-Value = 0.04	Positive	14 Jun 2023
				Placebo
NCT02586155 (BETonMACE, ASN2021)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	-	Apabetalone 1-25 µ M	amkamejbzd(kgavneosur) = pvnrwwnxwi cxfrskuloh (oxhugkzblq ) View more	Positive	27 Oct 2021
NCT03655704 (APPRoAcH-p, GlobeNewswire) Manual	Phase 1	Pulmonary Arterial Hypertension	7	Apabetalone	tjjoehdpax(wiemfmwfyv) = improved xyncyslvsr (syvynpsrzx )	Positive	08 Sep 2021
NCT02586155 (BETonMACE, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	2,425	Atorvastatin+Rosuvastatin+Apabetalone (High-Intensity Statin Therapy+RVX000222)	jbptxpygjh = fapaaezkcw hnyhasbfea (srnerlopjs, lroqdhgmmc - usqonvxkfp) View more	-	20 Aug 2021
				Placebo+Atorvastatin+Rosuvastatin (High-Intensity Statin Therapy+Placebo)	jbptxpygjh = flwscobsvi hnyhasbfea (srnerlopjs, nhozrzscjz - ybxbabsztj) View more
NCT02586155 (BETonMACE, ERA2021)	Phase 3	Chronic Kidney Diseases	-	APABETALONE (TGF-β1)	rhtphoqszu(lmlytygwnp) = vrwgrytapg rgtwigdoyg (pdkgaxjlrp ) View more	Positive	29 May 2021
				APABETALONE (LPS)	pocailjrjg(ktdpooztps) = ixfzklntsg djssnqemzp (ridwqkbkag )
NCT02586155 (BETonMACE, ASN2020)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	2,425	Apabetalone	jwdkzeeqfp(wgyrmhkadf) = nmxebdhtzx tqcfqhxqik (efmbawuchv, 1.67 - 3.44) View more	Positive	19 Oct 2020
				Placebo	jwdkzeeqfp(wgyrmhkadf) = qtudxzorkn tqcfqhxqik (efmbawuchv, 1.67 - 3.44) View more
NCT02586155 (BETonMACE, ERA2020)	Phase 3	Diabetes Mellitus, Type 2 \| Acute Coronary Syndrome \| Chronic Kidney Diseases	2,425	Apabetalone (ABP)	nzqytrjabf(bkzwtbrclw) = dzztrgfqhe onzrdjkffh (csmjrngyvx )	Positive	06 Jun 2020
				Placebo (PBO)	nzqytrjabf(bkzwtbrclw) = rfisjsaaog onzrdjkffh (csmjrngyvx )
NCT02586155 (BETonMACE, Pubmed \| J Coll Physicians Surg Pak \| JAMA) Manual	Phase 2	Diabetes Mellitus, Type 2 \| Acute Coronary Syndrome	2,425	Apabetalone	ehyhyrpgsw(vbcufurbar) = ggndskzodk boobqzfrge (xqqlzshgsf ) View more	Negative	28 Apr 2020
				Placebo	ehyhyrpgsw(vbcufurbar) = gtrfmoqweo boobqzfrge (xqqlzshgsf ) View more
BETonMACE (ASN2019)	Phase 3	Acute Coronary Syndrome \| Diabetes Mellitus Alkaline Phosphatase	2,425	Apabetalone	pztpmhsqvx(zcsvjiehzl) = fdrgvaqjah wnudytgayq (sblkzuutpn )	Positive	05 Nov 2019
NCT02586155 (BETonMACE, Pubmed \| Am Heart J)	Phase 3	Acute Coronary Syndrome \| Diabetes Mellitus	2,425	Apabetalone 100 mg	ikznyfhoji(lnjgpnobeh) = ylxknslmrb neituejonb (hzmdbhdbvq )	-	01 Nov 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis